Evaluation of the Antimicrobial Effectiveness of an Antimicrobial Cloth

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

99 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-06-21

Study Completion Date

2017-08-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Healthy volunteers will receive treatment to two body locations with the investigational product and placebo and the antimicrobial effectiveness of each treatment will be measured.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effectiveness of an Antimicrobial Agent for Preoperative Skin Preparation

NCT03224299

Preoperative Skin Preparation

COMPLETED PHASE2

Pilot Clinical Trial - Comparative Study of Two Material Concentration of OD-141309

NCT04703335

Infectious Disease

UNKNOWN EARLY_PHASE1

In Vivo Preoperative Skin Preparation Persistence Evaluation

NCT03155178

Bacterial Recovery of Skin Flora Post-product Application

COMPLETED PHASE2

Antimicrobial Efficacy of 2% CHG (Chlorhexidine Gluconate)

NCT02530541

Healthy

COMPLETED PHASE1/PHASE2

In Vivo Efficacy Study of Patient Preoperative Preps

NCT02203591

Bacterial Reduction Post-product Application

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Preoperative Skin Preparation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Investigational Product

Polyester cloth impregnated with investigational product

Group Type EXPERIMENTAL

Octenidine Dihydrocloride in aqueous solution

Intervention Type DRUG

application of investigational product

Vehicle Control (VC)

Polyester cloth impregnated with the vehicle control

Group Type PLACEBO_COMPARATOR

Vehicle Control

Intervention Type OTHER

application of vehicle control

Saline Control (SC)

Saline applied wtih polyester cloth

Group Type PLACEBO_COMPARATOR

Saline Control

Intervention Type OTHER

application of placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Octenidine Dihydrocloride in aqueous solution

application of investigational product

Intervention Type DRUG

Vehicle Control

application of vehicle control

Intervention Type OTHER

Saline Control

application of placebo

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males and/or females, at least 18 years or older and of any race.
* Are in good general health.
* Unable to become pregnant, or willing to use an acceptable method of contraception (i.e. oral contraception, intra-uterine device \[IUD\], diaphragm, condom, abstinence, bilateral Tubal ligation, or are in a monogamous relationship with a partner who has had a Vasectomy) to prevent pregnancy for at least 14 days immediately preceding Treatment Day and throughout the duration of the study, if female of child-bearing potential.
* All female subjects must have a negative urine pregnancy test on Treatment Day prior to any applications of the study products.
* Have skin within 6 inches of the test sites that is free of dermatoses, abrasions, cuts, lesions or other skin disorders.
* Cooperative and willing to follow Subject Instructions
* Cooperative and willing to sign Consent Form and HIPAA Authorization Form.
* Able to read, write and follow instructions in English.

Exclusion Criteria

* Exposure to topical or systemic antimicrobials or any other product known to affect the normal microbial flora of the skin, antibiotics or steroids (other than hormones for contraception or post-menopausal reasons) exposure within 14 days prior to Treatment Day and for the remainder of the study. Restrictions include, but are not limited to antimicrobial-containing soaps, antiperspirants/deodorants, shampoos, lotions, perfumes, after shaves, and colognes.
* Swimming in chemically treated pools or bathing in hot tubs, spas and whirlpools within 14 days prior to Treatment Day and for the remainder of the study.
* Use of tanning beds, hot waxes, or depilatories, including shaving (in the applicable test areas) within 14 days prior to Treatment Day and for the remainder of the study.
* Contact with strong detergents, solvents, acids, bases, bug repellant, fabric softener-treated clothing, UV treated clothing or other household chemicals in the applicable test areas within 14 days of the Treatment Day and for the remainder of the study.
* Subjects who have a history of sensitivity to vinyl, natural rubber latex, adhesive skin products (e.g., Band-Aids, medical tapes), polyester, metals, inks, common antibacterial agents found in common personal beauty or personal care soaps, lotions, or ointments
* Subjects who have asthma requiring medication, diabetes, hepatitis B or C, an organ transplant, mitral valve prolapse with a heart murmur, congenital heart disease, lupus, Crohn's disease, medicated multiple sclerosis, internal prosthesis or any immunocompromised conditions (such as AIDS or HIV positive).
* Subjects who have a history of skin allergies.
* Subjects who have a history of skin cancer within 6 inches of the applicable test areas or have received treatment for any type of internal cancer within the 5 years prior to enrollment.
* Any tattoos or scars on the test sites or within 2 inches of the test sites; skin blemishes or warts may be permissible with the specific approval of the Principal Investigator or consulting physician.
* Dermatoses, cuts, lesions, active skin rashes, scabs, breaks in the skin or other skin disorders within 6 inches on or around the test sites.
* A currently active skin disease or inflammatory skin condition (for example contact dermatitis; psoriasis, and eczema) anywhere on the body.
* Subjects who are pregnant, attempting pregnancy, or nursing.
* Subjects who have showered or bathed within at least 72 hours of the Treatment Day (sponge baths may be taken, however, the lower abdomen and upper thigh region must be avoided).
* Subjects who receive an irritation score of 1 (any redness, swelling, rash, or dryness present at any treatment area) for any individual skin condition prior to the Treatment Day baseline sample collection.
* Participation in another clinical trial in the 30 days prior to signing the informed consent for this study, current enrollment in another clinical trial, or have already participated in this study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes